



#17 chh
1-6-98
PATENT

Attorney Docket No.: 03495.0008-09000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.)
)
Serial No.: 08/466,921) Group Art Unit: 1813
)
Filed: June 6, 1995) Examiner: Jeffrey S. PARKIN

For: METHOD OF PRODUCING ANTIBODIES TO ANTIGENS OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JAN 02 1998

Sir:

RESPONSE TO PAPER NO. 15

This paper is filed in response to the Office Action of June 27, 1997 (Paper No. 15).

While a shortened statutory period for response was set to expire three months from the mailing date, filed herewith is a Petition for Extension of Time with the appropriate fee.

REMARKS

Reconsideration of this application is respectfully requested.

Claims 39-45 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to provide an enabling disclosure, since Applicants have failed to meet the biological deposit requirements. The Examiner contends that since the λ -J19 LAV clone is required to practice the invention, it must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. He further alleges that the specification does not provide for the aforementioned, and thus, the claims are not enabled. To overcome this rejection,

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D. C. 20005
202-408-4000